INSULET CORP — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 52/100
What the filing says
Insulet reported Q2 2026 revenue of $801.7M (23.5% YoY growth), exceeding guidance, with Omnipod revenue of $795.9M (+24.6%). U.S. Omnipod grew 20.1% to $544.1M; International grew 35.5% to $251.8M. However, the company lowered full-year 2026 guidance from 21-23% to 20-22% total revenue growth and U.S. Omnipod from 20-22% to 17-19%, citing learnings from type 2 diabetes expansion. Adjusted operating margin expanded ~140 bps to 19.3%; adjusted net income rose 37.4% to $115.0M ($1.66 EPS). The company issued voluntary medical device corrections (MDCs) in March and May 2026 (~$25M warranty impact in Q2).
Why this rating
Strong absolute Q2 beat offset by material guidance reduction—type 2 ramp slower than expected. ~$3.7B annual run rate at Q2 pace. Margin expansion positive; MDCs and guidance reset are cautionary. Neutral near-term outlook.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.